5,6-Dihydro-5-Fluorouracil-¹³C,¹⁵N₂  (Synonyms: 5-DHFU-¹³C,¹⁵N₂; 5-Fluorodihydropyrimidine-2,4-dione-¹³C,¹⁵N₂; 5-Fluorodihydrouracil-¹³C,¹⁵N₂)

5,6-Dihydro-5-Fluorouracil-¹³C,¹⁵N₂ (5-DHFU-¹³C,¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled 5,6-Dihydro-5-Fluorouracil (HY-134160). 5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC₅₀=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

135.07

5-DHFU-¹³C,¹⁵N₂; 5-Fluorodihydropyrimidine-2,4-dione-¹³C,¹⁵N₂; 5-Fluorodihydrouracil-¹³C,¹⁵N₂

C₃¹³CH₅F¹⁵N₂O₂

1189492-99-6

696-06-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fischel, et al. Lack of contribution of dihydrofluorouracil and α-fluoro-β-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes. Anticancer Drugs 15(10), 969-974 (2004).